[Form 4] Maravai LifeSciences Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

HSBC Holdings plc has filed a Form 6-K to confirm its current share capital and voting rights in line with the UK FCA Disclosure Guidance and Transparency Rule 5.6.1.

• Issued share capital: 17,477,916,261 ordinary shares of US$0.50 each as of 27 June 2025.
• Treasury shares: None are held; therefore every issued share carries a vote.
• Total voting rights: 17,477,916,261. Investors should use this denominator when assessing whether their holdings require disclosure under UK or Hong Kong regulations.
• Contact details for notifications are provided for Investor Relations and the Corporate Governance team.

The filing is procedural, updating the market on the company’s capital structure rather than announcing any operational or financial performance changes.

Positive

• Compliance clarity: Provides an updated, precise share and voting-rights figure, aiding investors in regulatory reporting.

Negative

• None.

Insights

Corporate Governance Specialist

TL;DR: Routine share-count update; neutral governance impact.

This Form 6-K simply restates HSBC’s issued share capital and confirms that no shares are held in treasury, keeping the market informed for regulatory threshold calculations. The unchanged share count signals stability in the equity base, with no dilution or buybacks disclosed. While essential for compliance under FCA DTR 5.6.1 and Hong Kong SFO Part XV, it carries no direct valuation or earnings implications. Investors may reference the figure when monitoring substantial shareholding notifications, but the filing is otherwise standard and non-impactful.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MARKER LUKE JOSEPH

(Last) (First) (Middle)

C/O GTCR, LLC

300 N. LASALLE SUITE 5600

(Street)

CHICAGO IL 60654

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/16/2025		A		89,139(1)	A	$2.16	138,055(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on June 16, 2025, which vest in full upon the earlier of one year from the date of grant or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

2. The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16.

Remarks:

	/s/ Kurt Oreshack, by power of attorney for Luke Marker	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ordinary shares does HSBC (HSBC) have in issue?

HSBC reports 17,477,916,261 ordinary shares in issue as of 27 June 2025.

Does HSBC hold any treasury shares?

No, HSBC holds zero treasury shares; every issued share carries a vote.

What is the total number of voting rights for HSBC?

The total number of voting rights equals the share count: 17,477,916,261.

Why is HSBC filing this Form 6-K update?

To comply with UK FCA Disclosure Guidance & Transparency Rule 5.6.1 and notify investors of the current voting-rights denominator.